Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1512-1520

  Braybrooke, Jeremy P ^a   Slade, Andrew ^b   Deplanque, Gael ^a   Harrop, Richard ^b   Madhusudan, Srinivasan ^a   Forster, Martin D ^a   Gibson, Rachel ^a   Makris, Andreas ^c   Talbot, Denis C ^a   Steiner, Jan ^b   White, Linda ^b   Kan, On ^b   Naylor, Stuart ^b   Carroll, Miles W ^b   Kingsman, Sue M ^b   Harris, Adrian L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5T4 ANTIBODY; ANTIBODY; BETA GALACTOSIDASE; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; GENE PRODUCT; METXIA P450; PRODRUG; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BACTERIAL GENE; BIOSAFETY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYP2B6 GENE; DRUG ACTIVATION; DRUG RESPONSE; ESCHERICHIA COLI; FATIGUE; FEMALE; GENE; GENE THERAPY; GENE TRANSFER; HEADACHE; HISTOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; INJECTION PAIN; INJECTION SITE REACTION; INTRATUMORAL DRUG ADMINISTRATION; LACZ GENE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; SKIN BIOPSY; SKIN NODULE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; TIME FACTORS; TREATMENT OUTCOME;

EID: 20044363101     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0155     Document Type: Article

References (24)

1. Kan O, Kingsman S, Naylor S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin Biol Ther 2002;2:857-68.
2. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rev 1981;65:89-95.
3. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-37.
4. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984;44:5156-60.
5. Russo JE, Hilton J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res 1988;48:2963-8.
6. Russo JE, Hilton J, Colvin OM. The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. Prog Clin Biol Res 1989;290:65-79.
7. Chen G, Waxman DJ. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem Pharmacol 1995;49:1691-701.
8. Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989;49:2344-50.
9. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995;55:581-9.
10. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997;25:985-93.
11. Jounaidi Y, Hecht JE, Waxman DJ. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998;58:4391-401.
12. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-34.
13. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int J Cancer 1997;71:267-74.
14. Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther 1997;4:1322-9.
15. Pierrefite-Carle V, Baque P, Gavelli A, et al. Subcutaneous or intrahepatic injection of suicide gene modified tumor cells induces a systemic antitumor response in a metastatic model of colon carcinoma in rats. Gut 2002;50:387-91.
16. Slingsby JH, Baban D, Sutton J, et al. Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency. Hum Gene Ther 2000;11:1439-51.
17. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995;69:7430-6.
18. Kan O, Griffiths L, Baban D, et al. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther 2001;8:473-82.
19. Woods AM, Wang WW, Shaw DM, et al. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer. Biochem J 2002;366:353-65.
20. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21:2508-18.
21. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995;1:1171-7.
22. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990;61:89-95.
23. Mulder WM, Stern PL, Stukart MJ, et al. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 1997;3:1923-30.
24. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.